A federal judge denied Suboxone manufacturers' request for phased discovery, citing concerns about hindering the search for scientific truth and impeding overall progress in the litigation.

Attorneys are working to set deadlines for addressing key legal issues. This careful planning is crucial for a fair and thorough battle ahead. The collective pursuit of justice and compensation remains active and ongoing.

The Judicial Panel on Multidistrict Litigation consolidated multiple Suboxone dental complication cases in Ohio, aiming to expedite legal proceedings and ensure consistent rulings.

Legal action surged as new lawsuits were filed against Indivior in federal courts, amplifying the urgency of addressing Suboxone’s alleged dental health implications.

September saw the first wave of lawsuits against Indivior and Reckitt Benckiser for Suboxone’s severe dental damage. This marked the start of a major legal offensive, seeking justice for many affected users.

The FTC championed consumers early in the year by securing settlements for those who missed initial payouts and tackling anti-competitive practices by Indivior and Reckitt Benckiser, ensuring fair market competition.

The FDA officially recognized the potential for medications like Suboxone film, which dissolves in the mouth, to cause significant dental problems, resulting in updated warnings on the drug's labeling and patient information.

Indivior settled with the U.S. Department of Justice for $600 million over allegations of misleading marketing practices for Suboxone. Reckitt Benckiser, Indivior's former parent company, settled criminal charges totaling $1.4 billion related to Suboxone's marketing, addressing claims of deceptive tactics and monopoly practices.

The FDA approved the first generic versions of Suboxone sublingual film, potentially increasing access to treatment while influencing ongoing legal and regulatory actions.

The FDA issued warnings about serious risks associated with long-term use of opioid pain medications, including Suboxone, highlighting concerns about addiction, overdose, and death.

Reports surfaced in 2007 linking Suboxone, particularly its film formulation, to severe dental issues. These concerns gained traction with compelling studies from Harvard Medical School in 2012 and 2013, documenting cases where patients suffered significant dental decay and erosion linked to prolonged Suboxone use.